Valbiotis SA (ALVAL) AI Stock Analysis

• Market Cap: €19.59M
• Dividend Yield: N/A
• Average Volume (3M): 58.40K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.23
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: FR
• Employees: 44
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -0.64
• Shares Outstanding: 15,910,365
• 10 Day Avg. Volume: 68,860
• 30 Day Avg. Volume: 58,395
• PEG Ratio: 0.07
• Price to Book (P/B): 1.29
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -10.04
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 50 Neutral
• Price Target: €1.00 ▼(-15.25%Downside)

Valbiotis SA's overall stock score is primarily influenced by its challenging financial performance, marked by negative margins and cash flow issues. Technical analysis provides a slightly positive short-term outlook, but long-term concerns persist. The valuation indicates substantial profitability challenges, typical for the industry.

Valbiotis SA Business Overview & Revenue Model

Company Description

Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.

How the Company Makes Money

Valbiotis SA generates revenue primarily through the development and commercialization of its plant-based health products. The company partners with major players in the health and nutrition industries to co-develop and distribute its products. These partnerships often involve licensing agreements, under which Valbiotis receives milestone payments for development achievements and royalties on product sales. Additionally, the company may engage in collaborative research projects that provide funding and enhance its product offerings. Valbiotis also invests in clinical trials to validate the efficacy of its compounds, which can lead to increased market acceptance and sales.

Valbiotis SA Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
4.73M	175.00K	4.73M	785.00K	298.00K	3.09M
	Gross Profit
2.67M	-2.44M	2.69M	767.00K	282.00K	3.09M
	EBIT
-7.16M	-10.42M	-7.16M	-14.05M	-10.87M	-5.41M
	EBITDA
-6.82M	-9.17M	-6.41M	-11.13M	-7.46M	-2.37M
	Net Income Common Stockholders
-7.37M	-10.03M	-7.37M	-12.31M	-8.68M	-3.83M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
7.42M	11.58M	25.02M	20.83M	21.82M	14.59M
	Total Assets
11.91M	19.61M	33.31M	27.17M	28.48M	21.00M
	Total Debt
2.80M	5.72M	6.88M	7.18M	7.59M	7.01M
	Net Debt
-4.62M	-5.86M	-18.14M	-13.65M	-14.23M	-7.57M
	Total Liabilities
4.50M	9.24M	13.71M	13.86M	14.25M	13.93M
	Stockholders Equity
7.41M	10.37M	19.60M	13.31M	14.23M	7.07M
Cash Flow		Free Cash Flow
-8.08M	-11.80M	-8.30M	-9.48M	-7.58M	2.36M
	Operating Cash Flow
-8.06M	-11.54M	-8.06M	-9.19M	-7.16M	2.69M
	Investing Cash Flow
-250.00K	-61.00K	-250.00K	-197.00K	-7.00K	-332.00K
	Financing Cash Flow
12.49M	-1.84M	12.49M	8.40M	14.40M	4.19M

Valbiotis SA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.18
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALVAL, the sentiment is Positive. The current price of 1.18 is above the 20-day moving average (MA) of 1.12, above the 50-day MA of 1.07, and below the 200-day MA of 1.27, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 57.00 is Neutral, neither overbought nor oversold. The STOCH value of 59.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ALVAL.

Valbiotis SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.28B	3.29	-45.38%	2.80%	16.77%	-0.08%
ALVAL	50 Neutral	€19.59M	―		―	―	―
CMVLF		$109.71M	―	-58.55%	―	―	―
ALTUV		€29.09M	645.31		3.26%	―	―

Valbiotis SA Corporate Events

Valbiotis Announces Monthly Voting Rights and Share Capital Update

Valbiotis has announced its monthly information on the total number of voting rights and shares making up its share capital as of February 28, 2025. The company emphasizes the importance of compliance with its statutes regarding threshold crossings, which require shareholders to notify the company if their holdings reach certain percentages of the company’s capital. This announcement highlights Valbiotis’ commitment to transparency and regulatory compliance, which is crucial for maintaining investor confidence and ensuring proper governance.

Valbiotis Introduces Lipidrive as a Safe Alternative to Red Yeast Rice

Valbiotis has introduced Lipidrive, a scientifically proven alternative to red yeast rice for cholesterol management, in response to potential regulatory changes in Europe. With health authorities questioning the safety of red yeast rice, Valbiotis offers a compliant solution that aligns with future regulations, potentially impacting the dietary supplement market by providing a safe and effective option for maintaining normal cholesterol levels.